Articles tagged "Multicenter studies"

2020 American Transplant Congress
Automated Monitoring of Four Urinary Biomarkers in Routine Surveillance Identifies Patients at Low and High Risk of Renal Allograft Injury
L. Sheward¹, J. Wedel¹, N. Rodig¹, R. Mannon², O. Bestard³, V. Dharnidharka⁴, D. Zurakowski¹, A. Kho¹, T. Blydt-Hansen⁵, M. Seifert², D. M. Briscoe¹
¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Bellvitge University Hospital, Barcelona, Spain, ⁴St Louis Children's Hospital, St Louis, MO, ⁵BC Children's Hospital, Vancouver, BC, Canada
*Purpose: Surveillance renal biopsy data indicate that up to 36% of clinically stable kidney allograft recipients have subclinical rejection, emphasizing the need to implement automated…
2020 American Transplant Congress
Impact of Extended- versus Immediate-Release Tacrolimus on One-Year Development of De Novo DSA and Chronic Immune Activation in Kidney Transplantation (ASTOUND Study)
A. Wiseman¹, D. Kaufman², A. Patel³, D. Wojciechowski⁴, A. Tambur⁵, J. Kim⁶, J. Schwartz⁶
¹University of Colorado Hospital, Aurora, CO, ²University of Wisconsin, Madison, WI, ³Henry Ford Hospital, Detroit, MS, ⁴Massachusetts General Hospital, Boston, MA, ⁵Northwestern University, Chicago, IL, ⁶Astellas Pharma Global Development, Northbrook, IL
*Purpose: To compare, using an adaptive study design, the 1-year incidence of a novel two-part composite endpoint consisting of de novo donor-specific antibody (dnDSA) formation…
2020 American Transplant Congress
History of Coronary Artery Disease Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: Coronary artery disease (CAD) is common in patients of advanced age and does not preclude liver transplantation (LT) if adequately treated. We aimed to…
2020 American Transplant Congress
Re-Establishing Abstinence after Alcohol Relapse after Early Transplant (LT) for Alcoholic Hepatitis (AH) Provides Survival Advantage
J. Rice¹, B. Lee², G. Therapondos³, G. Im⁴, A. Lazar², M. Lucey¹, E. Weinberg⁵, H. Han⁶, H. Maddur⁷, M. Ghobrial⁸, C. Hsu⁹, O. Fix¹⁰, S. Eswaran¹¹, K. Shetty¹², N. Jakhete¹², D. Victor⁸, D. Foley¹, N. Mehta², M. Rinella⁷, T. Schiano⁴, C. Mobley⁸, N. Terrault⁶
¹U of WI SMPH, Madison, WI, ²UCSF, San Francisco, CA, ³Oschner, New Orleans, LA, ⁴Mt Sinai, New York, NY, ⁵U Penn, Philadelphia, PA, ⁶USC, Los Angeles, CA, ⁷NW Univ, Chicago, IL, ⁸Houston Mdt, Houston, TX, ⁹GTown U, Washington, DC, ¹⁰Swed Med, Seattle, WA, ¹¹Rush Med C, Chicago, IL, ¹²U of MD, Baltimore, MD
*Purpose: Among the ACCELERATE-AH cohort: (i) Identify factors associated with re-established abstinence in patients with alcohol relapse after LT for alcoholic hepatitis (AH); (ii) Determine…
2020 American Transplant Congress
MELD is MELD is MELD? Geographic/ Center-Level Variation in Mortality for Patients with the Same MELD Score
T. Ishaque¹, A. B. Massie¹, A. B. Kernodle¹, S. Getsin¹, P. Chaing¹, J. G. Jacqueline Garonzik Wang¹, S. Gentry², D. Segev¹
¹Johns Hopkins University, Baltimore, MD, ²Department of Mathematics, United States Naval Academy, Annapolis, MD
*Purpose: Waitlist candidates living in areas with poor access to health care may have higher mortality risk compared to candidates with same MELD in other…
2020 American Transplant Congress
Frailty Prior to Hospital Discharge Predicts Mortality after Cirrhosis-Related Admissions
M. Serper¹, S. Tao², P. Garren¹, D. Peyton¹, M. A. Dunn², K. Reddy¹, A. Gougol², A. Duarte-Rojo²
¹University of Pennsylvania, Philadelphia, PA, ²University of Pittsburgh, Pittsburgh, PA
*Purpose: Inpatient frailty assessment and its utility in clinical care is understudied in liver transplant (LT) candidates. Study objectives were to quantify physical frailty among…
2020 American Transplant Congress
A Multicenter Analysis of the Proportion and Pattern of Unexplained HLA Antibodies in Kidney Recipients without a History of Sensitization
J. Lan¹, J. S. Gill¹, H. M. Gebel², R. A. Bray², R. Liwski³, A. Vinson⁴, A. Greenshields³, S. Dobrer⁵, O. Gunther⁵, K. Sherwood⁵, F. H. Claas⁶, S. Heidt⁶, G. Karahan⁶, J. Gill⁷, M. Gill¹, U. Varyani¹, P. Jindal¹, P. Keown⁵
¹Medicine, Division of Nephrology, University of British Columbia, Vancouver, BC, Canada, ²Pathology, Emory University, Atlanta, GA, ³Pathology, Dalhousie University, Halifax, NS, Canada, ⁴Nephrology, Dalhousie University, Halifax, NS, Canada, ⁵Pathology, University of British Columbia, Vancouver, BC, Canada, ⁶Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands, ⁷Nephrology, Emory University, Atlanta, GA
*Purpose: Previous studies report a high prevalence of unexplained antibody reactivities on the single antigen bead (SAB) test. In a contemporary multicenter cohort of non-sensitized…
2020 American Transplant Congress
Integrated Multicohort Analysis of Transcriptome Profiles Identifies Blood Gene Signature to Distinguish Rejection from Infection in Patients with Solid Organ Transplants
L. C. Murphy, A. Rao, M. Donato, P. Khatri
School of Medicine, Stanford University, Stanford, CA
*Purpose: Allograft rejection and infection are now leading causes of morbidity and mortality in transplant recipients. Current diagnosis relies on nonspecific markers of graft injury,…
2020 American Transplant Congress
Evolution of Molecular Lung Transplant Biopsy Assessment: Rejection Can be Detected in Mucosal as Well as Transbronchial Biopsies
M. D. Parkes¹, K. Halloran², P. Halloran², &. the INTERLUNG Study Group³
¹Alberta Transplant Applied Genomics Centre, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³., ., AB, Canada
*Purpose: We recently developed a Molecular Microscope® (MMDx) rejection assessment platform for mucosal biopsies from the third airway bifurcation (3BMB) and transbronchial biopsies (TBB) from…
2020 American Transplant Congress
Atrial Fibrillation Predicts Inferior Survival in Liver Transplant Recipients of Advanced Age in a Large Multicenter U.S. Cohort
M. German¹, A. Hristov¹, A. Lee¹, F. Osman¹, A. Kwong², D. Devuni³, C. Wang⁴, J. Boike⁵, J. Jo⁵, L. VanWagner⁵, M. Serper⁶, R. Sharma⁷, E. Verna⁷, J. Shor³, A. Koteish⁸, G. Sehmbey⁹, A. Seetharam⁹, N. John², Y. Patel¹⁰, M. Kappus¹⁰, T. Couri¹¹, S. Paul¹¹, R. Salgia¹², Q. Nhu¹³, C. Frenette¹³, J. Lai⁴, A. Goel², E. Spengler¹
¹U of Wisconsin, Madison, WI, ²Stanford, Palo Alto, CA, ³U of Massachusetts, Worcester, MA, ⁴U of California, San Francisco, CA, ⁵Northwestern, Chicago, IL, ⁶U of Pennsylvania, Philadelphia, PA, ⁷Columbia, New York, NY, ⁸Florida Hospital, Orlando, FL, ⁹U of Arizona, Phoenix, AZ, ¹⁰Duke, Durham, NC, ¹¹U of Chicago, Chicago, IL, ¹²Henry Ford Hospital, Detroit, MI, ¹³Scripps, San Diego, CA
*Purpose: More liver transplants (LT) are being performed in patients >65 years (y) - a population with higher rates of cardiovascular (CV) disease. It is…